A potential new pathway to treat cancer is actually called the Hippo pathway - and it's a key control in how our organs are perfectly suited to our bodies, despite differences in size.
Using mice genetically lacking an enzyme called Set7, the results show that methylation of a protein called Yap is critical for the function of the Hippo pathway. Loss of the Set7 enzyme resulted in cell growth and larger organs.
"So why don't we have miniature whales or gigantic bats? It turns out that there are specific pathways that tell cells when to grow and when to stop," says Colby Zaph, assistant professor of Pathology and Laboratory Medicine at the Biomedical Research Centre, who co-authored the study published in Developmental Cell. Zaph, along with postdoctoral research fellow Menno Oudhoff, uncovered that size differences could be manipulated after a specific chemical modification called methylation dramatically affected its function.
"It's too early to tell how successful modifying this pathway could be in terms of helping with treatment of cancer. But based on our results, drugs that may activate the Set7 enzyme – to stop cell growth – may be invaluable to fighting cancers with Hippo pathway mutations," says Zaph.
The pathway has gone relatively unchanged despite evolution and could play a crucial role in regenerative medicine, including in skin growth and liver regeneration.
"Harnessing these results to treat diseases is now the next step."
